Research programme: HIV-1 vaccine - Uvax Bio
Latest Information Update: 21 May 2023
At a glance
- Originator Uvax Bio
- Class Antiretrovirals; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical HIV-1 infections
Most Recent Events
- 26 Apr 2023 Uvax Bio holds the exclusive worldwide rights to the 1c-SApNP® platform and an expanding portfolio of 12 patented preclinical vaccine candidates
- 26 Apr 2023 Preclinical trials in HIV-1 infections (Prevention) in USA (Parenteral)
- 26 Apr 2023 Uvax Bio in collaboration with NIH plans a phase I trial for HIV-1 Infections in Q1 of 2024